SCHEMBL22493472

SCHEMBL22493472

CC(C)(C)NCCc1cccc(-c2cccc(F)c2)n1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TRPV3 Q8NET8 2/20 0.43
CTSL P07711 1/20 0.42
CTSB P07858 1/20 0.42
CTSS P25774 1/20 0.42
CTSK P43235 1/20 0.42
KCNH2 Q12809 1/20 0.42
CNR2 P34972 2/20 0.41
CNR1 P21554 1/20 0.41
MAP4K4 O95819 5/20 0.40
MAPT P10636 3/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
KDM4E B2RXH2 1/20 0.38
POLB P06746 2/20 0.38
KMO O15229 1/20 0.37
TP53 P04637 1/20 0.37
IDO1 P14902 1/20 0.36
TLR8 Q9NR97 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22493894 0.86 SCN9A (0.44) TRPV3CTSLCTSBCTSSCTSK
SCHEMBL22480829 0.85 TRPV3 (0.43) TRPV3CTSLCTSBCTSSCTSK
SCHEMBL22493470 0.84 CNR2 (0.44) TRPV3CTSLCTSBCTSSCTSK
SCHEMBL22493739 0.79 PDE10A (0.49) TRPV3CTSLCTSBCTSSCTSK
SCHEMBL22480758 0.79 TRPV3 (0.39) TRPV3CTSLCTSBCTSSCTSK
SCHEMBL22493434 0.78 CYP2A6 (0.50) TRPV3MAPTKMT2AKDM4E
SCHEMBL22493866 0.78 CNR2 (0.39) TRPV3CTSLCTSBCTSSCTSK
SCHEMBL27435355 0.77 PDE8A (0.38) TRPV3MAPTMEN1KMT2AKDM4E
SCHEMBL20878875 0.76 MAP4K4 (0.47) TRPV3CNR2CNR1MAP4K4MAPT
SCHEMBL26855283 0.74 MAP4K4 (0.46) TRPV3CNR2CNR1MAP4K4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024137506-A1 COMPOSITIONS AND METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS CURASEN THERAPEUTICS, INC. (US) 2024-06-27 WO disclosed
WO-2023225021-A1 COMPOSITIONS AND METHODS FOR TREATING PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) CURASEN THERAPEUTICS, INC. (US) 2023-11-23 WO disclosed
WO-2020198466-A9 BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME CURASEN THERAPEUTICS, INC. (US) 2020-12-30 WO disclosed
WO-2020198466-A1 BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME CURASEN THERAPEUTICS, INC. (US) 2020-10-01 WO disclosed